Daiichi Sankyo ADR logo

Daiichi Sankyo ADR

Stock
Stock
Ticker: DSNKY
DSNKY

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

Daiichi Sankyo ADR has so far distributed 0.241 in 2026. The next dividend will be paid on 17.12.2026


0.368

CHART BY

Frequently asked questions

The market capitalization of Daiichi Sankyo ADR is $32.88B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Daiichi Sankyo ADR is 19.59. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Daiichi Sankyo ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is 0.005952. EPS indicates the company's profitability on a per-share basis.
Currently, 17 analysts cover Daiichi Sankyo ADR's stock, with a consensus target price of $0.159. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Daiichi Sankyo ADR reported a revenue of $92.84M.
Daiichi Sankyo ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $13.45M. EBITDA measures the company's overall financial performance.
Daiichi Sankyo ADR has a free cash flow of $65.68K. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Daiichi Sankyo ADR employs approximately 20,171 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.

Financials

Market Cap 
$32.88B
EPS (TTM) 
0.005952
P/E ratio (TTM) 
19.59
Revenue (TTM) 
$92.84M
EBITDA (TTM) 
$13.45M
Free Cashflow (TTM) 
$65.68K

Analyst Ratings

The price target is $0.159 and the stock is covered by 17 analysts.

Buy

13

Hold

4

Sell

0

Information

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded in 2005 and is headquartered in Tokyo, Japan.

Employees
20,171
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
DSNKY

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation